Xanthus Pharmaceuticals Pages on BioPortfolio:

BioPortfolio - Biocorporate Search Cambridge
Xanthus Pharmaceuticals, Inc. Xanthus is a biopharmaceutical company focused on the discovery, development, acquisition and commercialization of ...
http://www.bioportfolio.com/biocorporate/search/city/Cambrid...

BioPortfolio - guanosine pentaphosphate
BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science ... guanosine tetraphosphate accumulation and induction of Myxococcus xanthus . ...
http://www.bioportfolio.com/search/guanosine_pentaphosphate_...

BioPortfolio - gc rich sequence wikipedia
BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug ... The xanthusBase core is the 9.14 Mb Myxococcus xanthus genome sequence, .
...
http://www.bioportfolio.com/search/gc_rich_sequence_wikipedi...

Biotech M&A Strategies: Deal assessments, trends and future prospects
Xanthus acquisition 66 Xanthus' assets 67 Impact of deal on Antisoma 68 Conclusion 69 ... Figure 6.16: Future trends in biotech/pharma M&A activity 98
...
http://www.bioportfolio.com/cgi-bin/acatalog/info_1131.html...

BioPortfolio - PSTK - phosphoseryl-tRNA kinase
BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug ... Fruiting body development of Myxococcus xanthus is propelled by temporal.
...
http://www.bioportfolio.com/gene/118672-PSTK.html...

BioPortfolio - Nitrate Reductase Nadh
BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery ... 6833447, Myxococcus xanthus genome sequences and uses thereof ...
http://www.bioportfolio.com/indepth/Nitrate_Reductase_Nadh.h...

BioPortfolio - Intramolecular Lyases Ec 5.5 research
BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science ... Conversion of the lycopene monocyclase of Myxococcus xanthus into a bicyclase.
...
http://www.bioportfolio.com/indepth/Intramolecular_Lyases_Ec...

BioPortfolio - Transferases Other Substituted Phosphate Groups ...
BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug ... differentially activate biosynthetic pathways in Myxococcus xanthus. ...
http://www.bioportfolio.com/indepth/Transferases_Other_Subst...

BioPortfolio - Jenapharm GmbH & Co. KG - Profile
The peptidoglycan sacculus of Myxococcus xanthus has unusual structural ... The acquisition of the pharmaceutical development company elbion GmbH completed ...
http://www.bioportfolio.com/biocorporate/25048-Jenapharm+Gmb...

BioPortfolio - COSMOlogic GmbH & Co. KG - Profile
The peptidoglycan sacculus of Myxococcus xanthus has unusual structural features ... Process Excellence and Six Sigma in the Pharmaceutical Industry - With ...
http://www.bioportfolio.com/biocorporate/21326-COSMOlogic%25...

Results from other life science and pharmaceutical sites:

BioSpace - Xanthus Pharmaceuticals, Inc. News, Search Jobs, Events
European Commission Grants Orphan Drug Designation to Xanthus Pharmaceuticals, Inc.'s Xanafide for the Treatment of Acute Myeloid Leukemia 10/26/2007 ...
http://www.biospace.com/company_profile.aspx?CompanyId=56022...

Xanthus Pharmaceuticals to Present at the BIO 2006 Annual ...
About Xanthus Pharmaceuticals, Inc. Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology candidates ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

BioSpace - Xanthus Pharmaceuticals, Inc. News, Search Jobs, Events
Xanthus Pharmaceuticals, Inc. Presents Updated Xanafide Phase 2 Data Showing ... Xanthus Pharmaceuticals, Inc. Announces Oral Fludarabine NDA Accepted for ...
http://www.biospace.com/company_profile.aspx?CompanyId=10013...

Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents ...
6 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a privately-held oncology drug development company, today announced that the Company has acquired from ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Antisoma PLC To Acquire Xanthus Pharmaceuticals, Inc. For USD ...
L) To Acquire Xanthus Pharmaceuticals, Inc. For USD $52.2M 5/16/2008 London, UK, May 16, 2008 - (ABN Newswire) - London, UK, and Boston, MA: 16 May 2008 ...
http://www.biospace.com/news_story.aspx?NewsEntityId=96840...

Xanthus Presents In Vitro Data Demonstrating that Symadex Is a ...
Xanthus licensed intellectual property related to Symadex from BTG International , Ltd. About Xanthus Pharmaceuticals, Inc. Xanthus Pharmaceuticals, ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Xanthus Pharmaceuticals, Inc. Meets Milestone In Phase 2 Clinical ...
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage , small-molecule oncology candidates through a management team whose ...
http://www.biospace.com/news_story.aspx?NewsEntityId=20556...

Xanthus' Symadex Can Reverse Disease in Preclinical Multiple ...
28 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a privately-held drug development company, today presented data that Symadex(TM) reverses the clinical
and ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Xanthus Pharmaceuticals, Inc. Receives Orphan Drug Designation for ...
(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., a privately-held oncology and autoimmune disease drug development company, today announced that the FDA has
...
http://www.biospace.com/news_story.aspx?NewsEntityId=81692...

American Society of Hematology – 48th Annual Meeting and ...
Xanthus's XLS-002 for the treatment of. hematological malignancies. MyDoanh Chau (Xanthus Pharmaceuticals Inc, USA) and. colleagues from the University of ...
http://www.biomedcentral.com/content/pdf/cd-761213.pdf...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.